Roche drug cocktail doubles chance of holding lung cancer at bay

Roche drug cocktail doubles chance of holding lung cancer at bay

The logo of Swiss pharmaceutical company Roche is seen outside their headquarters in Basel, Switzerland, January 30, 2014. REUTERS/Ruben Sprich/Files   ZURICH, December 7 (Reuters) – Adding Roche’s immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome some experts labelled unprecedented.   […]